Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 3:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 4,377 matching trials from the live ClinicalTrials.gov search.
Filters: "small cell lung cancer" Condition: Lung Cancer Clear all
Recruiting No phase listed Observational

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

NCT03452774
View directory record Official record
Conditions
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Stomach, Cancer Liver, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Cervix, Cancer of Colon, Cancer of Larynx, Cancer, Lung, Cancer, Breast, Cancer, Advanced, Cancer Prostate, Cancer of Neck, Cancer of Skin, Neuroendocrine Tumors, Carcinoma, Mismatch Repair Deficiency, BRCA Gene Rearrangement, Non Hodgkin Lymphoma, Leukemia, Non Small Cell Lung Cancer, Cholangiocarcinoma, Glioblastoma, Central Nervous System Tumor, Melanoma, Urothelial Carcinoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Testicular Cancer, Breast Cancer, COVID, Myelofibrosis, Myeloproliferative Neoplasm, Myeloproliferative Disorders, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes
Interventions
Clinical Trial Matching
Other
Lead sponsor
Massive Bio, Inc.
Industry
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2040
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 15, 2026, 3:03 AM EDT
Completed Not applicable Interventional

Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care

NCT01726296
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Squamous Cell Lung Cancer, Stage I Colon Cancer, Stage I Rectal Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Colon Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
Interventions
educational intervention, medical chart review
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 15, 2026, 3:03 AM EDT
Completed Phase 2 Interventional

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00118183
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
docetaxel, cetuximab, bortezomib
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 15, 2026, 3:03 AM EDT
Completed Phase 1 Interventional Results available

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT02595866
View directory record Official record
Conditions
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 15, 2026, 3:03 AM EDT
Completed Phase 1 Interventional

Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00062322
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, irinotecan hydrochloride, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2010 · Synced Oct 15, 2026, 3:03 AM EDT
Active, not recruiting Phase 2 Interventional

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

NCT06161441
View directory record Official record
Conditions
Resectable Non-small Cell Lung Cancer
Interventions
Fianlimab, Cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
8
States / cities
Clermont, Florida • Chicago, Illinois • Westwood, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 15, 2026, 3:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants

NCT06348888
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
Interventions
BAY2927088, Itraconazole, Carbamazepine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 15, 2026, 3:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer

NCT01607554
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Irinotecan
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 15, 2026, 3:03 AM EDT
Completed No phase listed Observational

A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer

NCT06686602
View directory record Official record
Conditions
Advanced/Metastatic NSCLC, Advanced/Metastatic HER2-negative Breast Cancer
Interventions
No drug
Other
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
13,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 15, 2026, 3:03 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

NCT03490669
View directory record Official record
Conditions
Advanced Solid Tumors, Pancreatic Cancer, Non Small Cell Lung Cancer, Ovarian Cancer
Interventions
MSC-1
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Scottsdale, Arizona • Grand Rapids, Michigan • Middletown, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 15, 2026, 3:03 AM EDT
Terminated No phase listed Observational

Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

NCT04676386
View directory record Official record
Conditions
NSCLC Stage IV, NSCLC, Stage IIIC
Interventions
Primary Immune Response (PIR) test by Biodesix, Inc.
Diagnostic Test
Lead sponsor
Addario Lung Cancer Medical Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
San Carlos, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 15, 2026, 3:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Breathe Easier II: A Dyad-based Multiple Behavior Intervention

NCT05956782
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, COPD, Self-Management, Physical Inactivity, Stress, Quality of Life
Interventions
Breathe Easier
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 15, 2026, 3:03 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00041054
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, etoposide, exisulind
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
81
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 15, 2026, 3:03 AM EDT
Terminated Phase 2 Interventional Results available

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

NCT04373369
View directory record Official record
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
Vorolanib, Atezolizumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 15, 2026, 3:03 AM EDT
Not listed Phase 1Phase 2 Interventional

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

NCT00100256
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Neoplasm Recurrence, Local
Interventions
Rhenium (Re 188 P2045, BAY86-5284)
Drug
Lead sponsor
Andarix Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
2
States / cities
Iowa City, Iowa • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 15, 2026, 3:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain

NCT02308020
View directory record Official record
Conditions
Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Brain Metastases
Interventions
Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Duarte, California • La Jolla, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 15, 2026, 3:03 AM EDT
Terminated Phase 1 Interventional Results available

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

NCT03881488
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
Interventions
CTX-471, Pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Compass Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Ocala, Florida • Port Saint Lucie, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 3:03 AM EDT
Completed Phase 2 Interventional

A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC

NCT00251524
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Bevacizumab, Oxaliplatin, Pemetrexed
Drug
Lead sponsor
Veeda Oncology
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2012 · Synced Oct 15, 2026, 3:03 AM EDT
Terminated Phase 3 Interventional Results available

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

NCT02588261
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
naquotinib mesilate, Erlotinib, Gefitinib
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
25
States / cities
Beverly Hills, California • Fountain Valley, California • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 15, 2026, 3:03 AM EDT
Terminated Phase 3 Interventional Results available

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

NCT05226598
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Cancer
Interventions
Pembrolizumab/Vibostolimab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed, Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
12
States / cities
Colorado Springs, Colorado • Fort Collins, Colorado • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 15, 2026, 3:03 AM EDT
Completed Phase 3 Interventional

Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery

NCT00003387
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, chemotherapy, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
47
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 15, 2026, 3:03 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

NCT02888743
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Durvalumab, Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 15, 2026, 3:03 AM EDT
Completed No phase listed Observational

Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy

NCT00310115
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
Smoking Prevention Usual Care, Counseling Intervention
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 15, 2026, 3:03 AM EDT
Terminated Phase 1 Interventional

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

NCT05652868
View directory record Official record
Conditions
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
Interventions
MYTX-011
Drug
Lead sponsor
Mythic Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 15, 2026, 3:03 AM EDT